A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes

Clinical Therapeutics

Volumn 30, Issue 11, 2008, Pages 1976-1987

  Hollander, Priscilla ^a   Cooper, John ^b   Bregnhøj, Jesper ^c   Pedersen, Claus Bang ^c  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b STAVANGER UNIVERSITY HOSPITAL   (Norway)

^c NOVO NORDISK A S   (Denmark)

Author keywords

basal insulin plus OAD; detemir; glargine; once daily; type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HEART ATRIUM FIBRILLATION; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; WEIGHT CHANGE;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; PATIENTS; POSTPRANDIAL PERIOD; TIME FACTORS; TREATMENT OUTCOME;

EID: 57649230070     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.11.001     Document Type: Article

References (30)

1. Lepore M., Pampanelli S., Fanelli C., et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 49 (2000) 2142-2148
2. Bolli G.B., and Owens D.R. Insulin glargine. Lancet 356 (2000) 443-445
3. Havelund S., Plum A., Ribel U., et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res 21 (2004) 1498-1504
4. Heise T., Nosek L., Ronn B.B., et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 53 (2004) 1614-1620
5. Klein O., Lynge J., Endahl L., et al. Albumin-bound basal insulin analogues (insulin detemir and NN344): Comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab 9 (2007) 290-299
6. Heise T., and Pieber T.R. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab 9 (2007) 648-659
7. Rosenstock J., Davies M., Home P.D., et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucoselowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 51 (2008) 408-416
8. Pieber T.R., Treichel H.C., Hompesch B., et al. Comparison of insulin detemir and insulin glargine in patients with type 1 diabetes using intensive insulin therapy. DiabetMed 24 (2007) 635-642
9. Devries J.H., Nattrass M., and Pieber T.R. Refining basal insulin therapy: What have we learned in the age of analogues?. Diabetes Metab Res Rev 23 (2007) 441-454
10. Alberti G. A desktop guide to type 2 diabetes mellitus. European Diabetes Policy Group 1998-1999 International Diabetes Federation European Region. Exp Clin Endocrinol Diabetes 107 (1999) 390-420
11. Riddle M.C., Rosenstock J., Gerich J., and for the Insulin Glargine 4002 Study Investigators. The treat-to-target trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26 (2003) 3080-3086
12. Lantus (insulin glargine) injection [product information].
13. http://www.emea.europa.eu/humandocs/PDFs/EPAR/Lantus/H-284-PI-en.pdf Accessed October 22, 2008.
14. Lantus (insulin glargine) injection [product information].
15. http://www.fda.gov/cder/foi/label/2004/21081s011Ibl.pdf Accessed October 22, 2008.
16. Kirkwood B.R., and Sterne J.A. Essential Medical Statistics. 2nd ed (2003), Blackwell Science, Malden, Mass
17. Garg S.K., Gottlieb P.A., Hisatomi M.E., et al. Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine. Diabetes Res Clin Pract 66 (2004) 49-56
18. Albright E.S., Desmond R., and Bell D.S. Efficacy of conversion from bedtime NPH insulin injection to once- or twice daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy. Diabetes Care 27 (2004) 632-633
19. Philis-Tsimikas A., Charpentier G., Clauson P., et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. [published correction appears in ClinTher. 2006;28:1967]. ClinTher 28 (2006) 1569-1581
20. Holman R.R., Thorne K.I., Farmer A.J., et al., for the 4-T Study Group. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl, J Med 357 (2007) 1716-1730
21. Hermansen K., Lund P., Clemmensen K., et al., for the Danish PREDICTIVE Study Group. 3-Month results from Denmark within the globally prospective and observational study to evaluate insulin detemir treatment in type 1 and type 2 diabetes: The PREDICTIVE Study. Rev Diabet Stud 4 (2007) 89-97
22. Haak T., Tiengo A., Draeger E., et al. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 7 (2005) 56-64
23. Raslova K., Bogoev M., Raz I., et al. Insulin detemir and insulin aspart: A promising basal-bolus regimen for type 2 diabetes. [published correction appears in DiabetesResClin Pract. 2006;72:112]. Diabetes Res Clin Pract 66 (2004) 193-201
24. Hermansen K., Davies M., Derezinski T., et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucoselowering drugs in insulin-naive people with type 2 diabetes. [published correction appears in Diabetes Care. 2007;30:1035]. Diabetes Care 29 (2006) 1269-1274
25. Standl E., Lang H., and Roberts A. The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes. Diabetes Technol Ther 6 (2004) 579-588
26. Hermansen K., Fontaine P., Kukolja K.K., et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 47 (2004) 622-629
27. De Leeuw I., Vague P., Selam J.L., et al. Insulin detemir used in basal-bolus therapy in people with type 1 diabe tes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 7 (2005) 73-82
28. Bartley P.C., Bogoev M., Larsen J., and Philotheou A. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: A 2-year, randomized, controlled trial. Diabet Med 25 (2008) 442-449
29. Hermansen K., and Davies M. Does insulin detemir have a role in reducing risk of insulin-associated weight gain?. Diabetes Obes Metab 9 (2007) 209-217
30. Korytkowski M. When oral agents fail: Practical barriers to starting insulin. Int J Obes Relat Metab Disord 26 Suppl 3 (2002) S18-S24